Zydus在2016年AASLD肝脏会议提供沙格列酮的新科学数据

StephenW

Zydus to Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA

News provided by
Zydus Cadila

Oct 31, 2016, 07:57 ET

Share this article

AHMEDABAD, India, October 31, 2016 /PRNewswire/ --

Zydus Cadila today announced that new data of Saroglitazar will be presented at The Liver Meeting® being held at the John B. Hynes Veterans Memorial Convention Center, Boston from 11th to 15th of November 2016.

Scientific abstract describing the attenuating effect of Saroglitazar on hepatic inflammation, oxidative stress and fibrosis in models of NAFLD/NASH will be presented on November 13, 12:30 pm to2:00 pm ET. The abstract can now be viewed at the AASLD website at http://www.aasld.org. Zydus Cadila will also host the booth 535 at the Hayes Hall D Exhibition Centre.

NASH is a hepatic manifestation of increased triglyceride accumulation in the liver leading to inflammation, fibrosis, cirrhosis and liver failure. NASH ranks as one of the major causes of Liver Transplant in United States and Europe, after hepatitis C. Biotech Analysts estimate the worldwide market for NASH medicines to reach USD 35-40 billion by 2025.

Speaking on the announcement, Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus Cadila said, "The study results have demonstrated that Saroglitazar has anti-fibrotic effect combined with strong efficacy in reducing fat and inflammation from the liver. The economic and clinical burden of nonalcoholic fatty liver disease (NAFLD) is rising exponentially and currently there is no approved treatment for NASH. Zydus is committed to developing Saroglitazar as a potential treatment option for millions of patients suffering from NASH."

Saroglitazar (Lipaglyn™), a novel PPARα/γ agonist having predominant PPAR alpha activity, was launched in India as a prescription medicine for the treatment of Hypertriglyceridemia and Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins. Since its launch in September 2013, more than 300,000 patients have been treated with Lipaglyn™ in India, and data has been presented at several scientific and medical conferences.

Saroglitazar is currently being evaluated in several clinical trials, including the Biomarkers driven Non-invasive Phase 2 "EVIDENCES-II" clinical study in USA, and a separate Biopsy-driven Phase 3 trial "EVIDENCES-III" in patients with NASH in India and other countries.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. For more information, please visit http://www.zyduscadila.com

SOURCE Zydus Cadila

StephenW

Zydus在2016年AASLD肝脏会议提供沙格列酮的新科学数据
Zydus在2016年AASLD肝脏会议上在美国波士顿举行的研究性沙格列酮的新科学数据

新闻提供
Zydus Cadila

2016年10月31日，07:57

分享此文章

印度AHMEDABAD，2016年10月31日/美通社/ -

Zydus Cadila今天宣布，Saroglitazar的新数据将在2016年11月11日至15日在波士顿John B. Hynes退伍军人纪念会议中心举行的The LiverMeeting®会议上公布。

描述Saroglitazar对NAFLD / NASH模型中肝炎症，氧化应激和纤维化的减毒作用的科学摘要将在11月13日12:30 pm至2:00 pm提供。摘要现在可以在AASLD网站http://www.aasld.org上查看。 Zydus Cadila还将在Hayes Hall D展览中心举办535展位。

NASH是肝脏中增加的甘油三酯积累的肝脏表现，导致炎症，纤维化，肝硬化和肝衰竭。 NASH在美国和欧洲，在丙型肝炎后，被列为肝移植的主要原因之一。生物技术分析师估计到2025年NASH药物的全球市场将达到35-40亿美元。

Zydus Cadila董事长兼董事总经理Pankaj R. Patel先生表示：“研究结果表明，沙格列酮具有抗纤维化作用，同时具有减少肝脏脂肪和炎症的强大功效，经济和非酒精性脂肪性肝病（NAFLD）的临床负担呈指数上升，目前还没有批准用于NASH的治疗.Zydus致力于开发Saroglitazar作为数百万患有NASH的患者的潜在治疗选择。

在印度推出了具有主要PPARα活性的新型PPARα/γ激动剂--Sriroglitazar（Lipaglyn TM）作为处方药，用于治疗不受他汀类药物控制的2型糖尿病患者的高甘油三酯血症和糖尿病性血脂异常。自2013年9月推出以来，超过300,000名患者在印度接受Lipaglyn™治疗，数据已经在几个科学和医学会议上提交。

Saroglitazar目前正在几个临床试验中进行评估，包括在美国的生物标志物驱动的非侵入性2期“EVIDENCES-II”临床研究和在印度NASH患者的单独的活检驱动的3期试验“EVIDENCES-III”其他国家。

关于Zydus

Zydus Cadila是一家创新的全球制药公司，发现，开发，制造和销售广泛的医疗治疗，包括小分子药物，生物治疗和疫苗。有关更多信息，请访问http://www.zyduscadila.com